Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

eceivable 16,927 15,534

Other current assets 4,037 6,082

Plant and equipment, net of accumulated

depreciation and amortization 337 19,849

Debt issuance costs 8,248 5,569

Other assets, net of accumulated amortization 13,465 9,633

Total assets $361,489 $224,740

Liabilities and Stockholders' Equity (Deficit)

Current liabilities $28,927 $25,423

Current notes payable 191,265 19,044

Long-term notes payable and other liabilities 350,995 373,517

Total liabilities 571,187 417,984

Paid-in capital and common stock 681,536 677,520

Accumulated other comprehensive loss (500) (1,892)

Accumulated deficit (890,734) (868,872)

Net stockholders' deficit (209,698) (193,244)

Total liabilities and stockholders' deficit $361,489 $224,740

About NPS Pharmaceuticals

NPS develops small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.

Conference Call Information

A conference call will be held today at 5:00 p.m. ET. To participate in the call, dial (866) 770-7051 with passcode 53288322. International callers may dial (617) 213-8064 using the same passcode. In addition, live audio of the conference call will be simultaneously broadcast over the Internet
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... January 14, 2014 Date: Friday, April 11, ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... organization solely dedicated to finding a cure for hepatitis B ... will host its annual Crystal Ball on Friday, April 11 ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Therapies to Address the Underlying Cause of Cystic,Fibrosis; ... SOUTH PLAINFIELD, N.J., Aug. 20 New ... that the investigational oral drug,PTC124 demonstrates activity in ... with PTC124 results in statistically significant,improvements in the ...
... Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ONY) announced today that ... on August 14, 2008 indicating that Oncothyreon does ... The NASDAQ Global Market,because it does not meet ... (i) the market value of Oncothyreon,s common stock ...
... Crystal Research Associates, LLC,announced today that ... on Generex Biotechnology Corporation (Nasdaq: GNBT ... at http://www.crystalra.com ., Generex Biotechnology ... pharmaceutical company that aims to research, develop, ...
Cached Biology Technology:PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 2PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 3PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 4PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 5Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 2Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 3
(Date:4/22/2014)... of Yale researchers will lead a five-year, $3 million ... events is affecting the transport of dissolved organic matter ... say could alter the chemical composition and water quality ... funding from the National Science Foundation,s MacroSystems Biology program, ... the watershed, which begins in Canada and runs through ...
(Date:4/22/2014)... fist-like club of a mantis shrimp, a team of ... with University of Southern California and Purdue University, have ... more impact resistant and tougher than the standard used ... of this tiny crustacean, the more we realize its ... day," said David Kisailus, a Kavli Fellow of the ...
(Date:4/22/2014)... The Federation of American Societies for Experimental Biology (FASEB) ... (FY) 2013 highlighting how funding from the National Institutes ... DC, and Puerto Rico. "FASEB is pleased to make ... the significance of NIH to their state," said FASEB ... nation,s leading source for biomedical research funding, investing ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3
... of children with undiagnosed learning disorders, developmental deficits, and ... challenges, which are explored in detail in a reflective ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ... ahead of print at www.liebertpub.com/gtmb ...
... been extinct for 65 million years, newly published data ... is providing invaluable insights into their paleobiology. Ammonites, shelled ... inhabited the oceans for nearly 350 million years. Specimens ... that covered North America during the Cretaceous Period demonstrate ...
... are investigating a potential new treatment for lung disease that ... is studying how statins, drugs which are commonly used to ... , There is currently no effective treatment for acute ... rates for those who become critically ill and suffer lung ...
Cached Biology News:Unexplained childhood disorders 2New discoveries in North America's Great Plains bring ammonites to life 2New discoveries in North America's Great Plains bring ammonites to life 3Queen's University Belfast lung injury study could save lives in critically ill 2